Rie Shiokawa

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.

A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.

R. Agarwal, U. Banerji, J. Spicer, 2012 .

Analysis of in Vitro Skin Permeation of 22-Oxacalcitriol Having a Complicated Metabolic Pathway

K. Sugibayashi, Toshinori Yamamoto, Y. Aso, 2006, Pharmaceutical Research.

An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying.

T. Peeters, O. Cynshi, K. Yogo, 2009, European journal of pharmacology.

Antigen-Dependent Internalization Is Related to Rapid Elimination from Plasma of Humanized Anti-HM1.24 Monoclonal Antibody

M. Nanami, Yuko Hirota, Yoshitaka Tanaka, 2010, Drug Metabolism and Disposition.

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.